Business
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
Initiation of Phase 3 MASH trial planned for 2026 Pemvidutide granted FDA Breakthrough Therapy Designation in MASH Topline data from RECLAIM Phase 2 trial of
About this update from Altimmune, Inc.
[{"type":"text","content":"Initiation of Phase 3 MASH trial planned for 2026 Pemvidutide granted FDA Breakthrough Therapy Designation in MASH Topline data from RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder (AUD) expected in third quarter 2026 Cash, cash equivalents and short-term investments of $274 million as of December 31, 2025; Balance sheet further strengthened through $75 million registered direct offering in January 2026 Webcast to be held today, March 5, 2026, at 8:30 a.m. ET GAITHERSBURG, Md., March 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update. “In pemvidutide, we have a unique and differentiated compound with the potential to address critical unmet needs of patients with serious liver diseases such as MASH. We are committed to taking the necessary steps to realize its value for all of our stakeholders and have significantly progressed our efforts to strengthen our financial and operational foundation,” said Jerry Durso, President and Chief Executive Officer of Altimmune. “We remain focused on ensuring that we have the means and the capabilities to successfully execute Phase 3 development in MASH and capture the significant opportunities ahead of us. We have a number of important inflection points in 2026, most notably the upcoming initiation of our Phase 3 trial of pemvidutide in MASH, for which we are actively finalizing the study plan. Finally, we look forward to the topline data from our RECLAIM Phase 2 trial of pemvidutide in AUD, which we expect to release in the third quarter.” Recent Highlights and Anticipated Milestones Metabolic Dysfunction-Associated Steatohepatitis (MASH) Positive 48-week data from IMPACT Phase 2b trial reported in December 2025 Statistically significant improvements observed in key non-invasive markers of fibrosis and inflammation, such as Enhanced Liver Fibrosis (ELF) and Liver Stiffness Measurement (LSM), with continued reductions from 24-week timepoint These markers are strongly associated with MASH histologic changesThese results build upon the statistically significant MASH resolution and positive trends in fibrosis improvement observed at 24 weeks Addi...